CN111096947A - Oral amisulpride solution - Google Patents

Oral amisulpride solution Download PDF

Info

Publication number
CN111096947A
CN111096947A CN201811251080.2A CN201811251080A CN111096947A CN 111096947 A CN111096947 A CN 111096947A CN 201811251080 A CN201811251080 A CN 201811251080A CN 111096947 A CN111096947 A CN 111096947A
Authority
CN
China
Prior art keywords
amisulpride
cyclodextrin
oral
solution
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811251080.2A
Other languages
Chinese (zh)
Inventor
李春
王宇杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Wanquan Dezhong Medical Biological Technology Co Ltd
Original Assignee
Beijing Wanquan Dezhong Medical Biological Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Wanquan Dezhong Medical Biological Technology Co Ltd filed Critical Beijing Wanquan Dezhong Medical Biological Technology Co Ltd
Priority to CN201811251080.2A priority Critical patent/CN111096947A/en
Publication of CN111096947A publication Critical patent/CN111096947A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a pharmaceutical solution suitable for oral administration comprising amisulpride, cyclodextrin or a derivative thereof, a suitable pharmaceutically acceptable solvent system and other excipients. The cyclodextrin or the derivative thereof and the drug cosolvent system can obviously increase the solubility of amisulpride in the solvent system, promote drug absorption and enhance the treatment effect. The oral liquid preparation of amisulpride has the advantages of high absorption speed, quick drug effect exertion, convenient taking and easy dosage division, and can simultaneously meet various requirements of clinical medication, patient compliance, industrialized mass production and the like.

Description

Oral amisulpride solution
Technical Field
The present invention relates to an amisulpride pharmaceutical solution suitable for oral administration.
Background
Amisulpride is an atypical antipsychotic drug used for the treatment of paranoid progressive schizophrenia, acute empty psychosis, and for the treatment of defective states of schizophrenia, residual psychotic development and depressive states associated with dullness. Early diagnosis and treatment of such diseases can significantly improve their recovery and outcome. Furthermore, early therapeutic intervention can avoid costly hospitalizations.
At present, the dosage form of amisulpride on the market at home and abroad is a tablet. The amisulpride oral solution can meet the specific requirements of patients suffering from paranoid progressive schizophrenia and acute empty psychosis, and the patients have difficulty in swallowing solid oral preparations. Oral solutions also allow physicians greater flexibility in designing dosage regimens for their patients. However, amisulpride is a poorly soluble drug, and the difficulty in preparing amisulpride oral solutions is to increase the solubility of the drug in the solvent system, while masking the unpleasant taste of the drug and maintaining a good taste.
Disclosure of Invention
Accordingly, the present invention provides an oral amisulpride solution comprising amisulpride, cyclodextrin or a derivative thereof, a suitable pharmaceutically acceptable solvent system and other excipients.
The cyclodextrin or the derivative thereof is α -cyclodextrin or the derivative thereof, β -cyclodextrin or the derivative thereof, and gamma-cyclodextrin or the derivative thereof.
The cyclodextrin is hydroxypropyl- β cyclodextrin.
The suitable pharmaceutically acceptable solvent system is comprised of one or more solvents selected from the group consisting of water, surfactants, and water-miscible solvents.
The water-miscible solvent is selected from ethanol, glycerol, propylene glycol, sorbitol solution, polyethylene glycol.
The surfactant is a pharmaceutically acceptable surfactant having a hydrophilic-lipophilic balance (HBL) of not less than 15.
The other auxiliary materials comprise a preservative, a flavoring agent and a pH regulator.
The amisulpride oral solution comprises 2-8% (w/v) of amisulpride, 2-40% (w/v) of hydroxypropyl- β -cyclodextrin, 10-40% (w/v) of propylene glycol, 0.05% (w/v) of tween 80, a preservative, a pH regulator, a flavoring agent and the balance of water.
The oral solution of amisulpride comprises 5% (w/v) of amisulpride, 25% (w/v) of hydroxypropyl- β -cyclodextrin, 20% (w/v) of propylene glycol, 20% (w/v) of sorbitol, 0.05% (w/v) of saccharin sodium, 0.05% (w/v) of tween 80, a proper amount of sodium hydroxide and the balance of water.
Examples
The present invention will be described in detail with reference to examples
The present invention is specifically illustrated by way of examples, but is not limited to the following examples.
Example 1
1000mL of an oral solution of amisulpride with a concentration of 5% (w/v) was prepared, which contained 50g of amisulpride, 150g of hydroxypropyl- β -cyclodextrin, 300mL of propylene glycol, 200mL of 70% sorbitol, 0.5g of Tween 80, 0.1g of ethylparaben, 0.5g of sodium saccharin, a suitable amount of sodium hydroxide, and distilled water was added to 1000 mL.
The preparation method comprises the steps of firstly adding 0.5g of Tween 80 into 200ml of distilled water, adding 150g of hydroxypropyl- β cyclodextrin, stirring, continuously adding 300ml of propylene glycol, stirring uniformly, adding 50g of amisulpride into a hydroxypropyl- β cyclodextrin solution under continuous stirring to obtain an amisulpride inclusion compound solution, then adding 200ml of 70% sorbitol solution, 0.1g of ethylparaben and 0.5g of saccharin sodium, adjusting the pH to 3.5 by using 1mol/L of sodium hydroxide solution, diluting the obtained solution to 1000ml by using distilled water, and filtering to obtain the amisulpride oral solution.
Example 2
1000mL of an oral solution of amisulpride with a concentration of 8% (w/v) was prepared, which contained 80g of amisulpride, 240g of hydroxypropyl- β -cyclodextrin, 200mL of propylene glycol, 200mL of 70% sorbitol, 0.5g of Tween 80, 0.1g of benzoic acid, 0.5g of sodium saccharin, a suitable amount of sodium hydroxide, and distilled water was added to 1000 mL.
The preparation method comprises the steps of firstly adding 0.5g of Tween 80 into 200ml of distilled water, adding 240g of hydroxypropyl- β cyclodextrin, stirring, continuously adding 200ml of propylene glycol, stirring uniformly, adding 80g of amisulpride into a hydroxypropyl- β cyclodextrin solution under continuous stirring to obtain an amisulpride inclusion compound solution, then adding 200ml of 70% sorbitol solution, 0.1g of benzoic acid and 0.5g of saccharin sodium, adjusting the pH value to 3.5 by using 1mol/L of sodium hydroxide solution, diluting the obtained solution to 1000ml by using distilled water, and filtering to obtain the amisulpride oral solution.
Example 3
1000mL of an oral solution of amisulpride with a concentration of 2% (w/v) was prepared, which contained 20g of amisulpride, 100g of hydroxypropyl- β -cyclodextrin, 400mL of propylene glycol, 200mL of 70% sorbitol, 0.5g of Tween 80, 0.1g of benzoic acid, 0.5g of sodium saccharin, a suitable amount of sodium hydroxide, and distilled water was added to 1000 mL.
The preparation method comprises the steps of firstly adding 0.5g of Tween 80 into 200ml of distilled water, adding 100g of hydroxypropyl- β cyclodextrin, stirring, continuously adding 400ml of propylene glycol, stirring uniformly, adding 20g of amisulpride into a hydroxypropyl- β cyclodextrin solution under continuous stirring to obtain an amisulpride inclusion compound solution, then adding 200ml of 70% sorbitol solution, 0.1g of benzoic acid and 0.5g of saccharin sodium, adjusting the pH value to 3.5 by using 1mol/L of sodium hydroxide solution, diluting the obtained solution to 1000ml by using distilled water, and filtering to obtain the amisulpride oral solution.
Example 4
1000mL of an oral solution of amisulpride with a concentration of 5% (w/v) was prepared, which contained 50g of amisulpride, 250g of hydroxypropyl- β -cyclodextrin, 200mL of propylene glycol, 200mL of 70% sorbitol, 0.5g of Tween 80, 0.1g of ethylparaben, 0.5g of sodium saccharin, a suitable amount of sodium hydroxide, and distilled water was added to 1000 mL.
The preparation method comprises the steps of firstly adding 0.5g of Tween 80 into 200ml of distilled water, adding 250g of hydroxypropyl- β cyclodextrin, stirring, continuously adding 200ml of propylene glycol, stirring uniformly, adding 50g of amisulpride into a hydroxypropyl- β cyclodextrin solution under continuous stirring to obtain an amisulpride inclusion compound solution, then adding 200ml of 70% sorbitol solution, 0.1g of ethylparaben and 0.5g of saccharin sodium, adjusting the pH to 3.5 by using 1mol/L of sodium hydroxide solution, diluting the obtained solution to 1000ml by using distilled water, and filtering to obtain the amisulpride oral solution.
Example 5
1000mL of an oral solution of amisulpride at a concentration of 5% (w/v) was prepared, which contained 50g of amisulpride, 250g of hydroxypropyl- β -cyclodextrin, 200mL of propylene glycol, 200mL of 70% sorbitol, 1.0g of sodium lauryl sulfate, 0.1g of ethylparaben, 0.5g of sodium saccharin, an appropriate amount of sodium hydroxide, and distilled water was added to 1000 mL.
The preparation method comprises the steps of firstly adding 1.0g of sodium dodecyl sulfate into 200ml of distilled water, adding 250g of hydroxypropyl- β cyclodextrin, stirring, continuously adding 200ml of propylene glycol, stirring uniformly, adding 50g of amisulpride into a hydroxypropyl- β cyclodextrin solution under continuous stirring to obtain an amisulpride inclusion compound solution, then adding 200ml of 70% sorbitol solution, 0.1g of ethyl hydroxybenzoate and 0.5g of saccharin sodium, adjusting the pH to 3.5 by using 1mol/L of sodium hydroxide solution, diluting the obtained solution to 1000ml by using distilled water, and filtering to obtain the amisulpride oral solution.
The effect factor experiment of amisulpride oral liquid formulations described in examples 1 and 5 was followed.
An influence factor experiment is carried out on the oral liquid preparation of amisulpride described in examples 1 and 5 according to the 2015 version of the guidance principle 9001 of the four parts of Chinese pharmacopoeia and the guidance principle of the stability of the bulk drug and the pharmaceutical preparation. And (3) performing high temperature 60 ℃ (10 days), low temperature-40 ℃ (3 circulation for 12 days), freeze thawing-40 ℃ (3 circulation for 12 days), and lighting experiment (10 days), sampling, lofting influencing factor samples under various conditions, and detecting according to stability focus investigation items. The results are shown in Table 1.
Table 1 examples 1 and 5 influence factor test results
Figure RE-RE-DEST_PATH_IMAGE001
The results show that: examples 1 and 5 stable oral solutions can be prepared using the formulations and processes provided by the present invention.
Accelerated testing of amisulpride oral liquid formulations described in example 1.
An accelerated experiment was performed on the oral liquid preparation described in example 1 according to 2015 edition of the four guidelines 9001 of the chinese pharmacopoeia for stability of bulk drug and pharmaceutical preparation. Three batches of amisulpride oral solution prepared in example 1 are taken and packaged according to a package material which is planned to be sold on the market, placed for 6 months under the conditions that the temperature is 40 +/-2 ℃ and the relative humidity is 60 +/-5 percent, and sampled for 1 month, 2 months, 3 months and 6 months during the test period, and the test is carried out according to key research items. The results of the accelerated test are shown in Table 2.
Table 2 example 1 accelerated test results
Figure RE-367138DEST_PATH_IMAGE002
The stability test of the oral amisulpride solution prepared in example 1 for 6 months is accelerated, and compared with 0 month, the tests have no obvious change, which shows that the oral amisulpride liquid preparation prepared in example 1 has good stability and stable process.

Claims (9)

1. An oral amisulpride solution, which is characterized by comprising amisulpride, cyclodextrin or derivatives thereof, a suitable medicinal solvent system and other auxiliary materials.
2. Amisulpride oral solution according to claim 1, wherein the cyclodextrin or derivative thereof is α -cyclodextrin or derivative thereof, β -cyclodextrin or derivative thereof, γ -cyclodextrin or derivative thereof.
3. Amisulpride oral solution according to claim 2, wherein the cyclodextrin is hydroxypropyl- β cyclodextrin.
4. Amisulpride oral solution according to claim 1, wherein the suitable pharmaceutically acceptable solvent system consists of one or more selected from water, surfactants, water-miscible solvents.
5. Amisulpride oral solution according to claim 4, characterized in that the water-miscible solvent is selected from ethanol, glycerol, propylene glycol, sorbitol solution, polyethylene glycol.
6. Amisulpride oral solution according to claim 4, characterized in that the surfactant is a pharmaceutically acceptable surfactant having a hydrophilic-lipophilic balance (HBL) of not less than 15.
7. Amisulpride oral solution according to claim 1, wherein the other excipients include preservatives, flavouring agents and pH adjusting agents.
8. The amisulpride oral solution of claim 1, which comprises 2-8% (w/v) amisulpride, 2-40% (w/v) hydroxypropyl- β -cyclodextrin, 10-40% (w/v) propylene glycol, 0.05% (w/v) tween 80, a preservative, a pH regulator, a flavoring agent, and the balance water.
9. The oral solution of amisulpride according to claim 1, which comprises 5% (w/v) amisulpride, 25% (w/v) hydroxypropyl- β -cyclodextrin, 20% (w/v) propylene glycol, 20% (w/v) sorbitol, 0.05% (w/v) sodium saccharin, 0.05% (w/v) Tween 80, a suitable amount of sodium hydroxide, and the balance water.
CN201811251080.2A 2018-10-25 2018-10-25 Oral amisulpride solution Pending CN111096947A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811251080.2A CN111096947A (en) 2018-10-25 2018-10-25 Oral amisulpride solution

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811251080.2A CN111096947A (en) 2018-10-25 2018-10-25 Oral amisulpride solution

Publications (1)

Publication Number Publication Date
CN111096947A true CN111096947A (en) 2020-05-05

Family

ID=70417703

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811251080.2A Pending CN111096947A (en) 2018-10-25 2018-10-25 Oral amisulpride solution

Country Status (1)

Country Link
CN (1) CN111096947A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114088845A (en) * 2021-12-06 2022-02-25 广东金城金素制药有限公司 Analysis method for determining content of saccharin sodium and benzamide degradation impurities in amisulpride oral solution

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114088845A (en) * 2021-12-06 2022-02-25 广东金城金素制药有限公司 Analysis method for determining content of saccharin sodium and benzamide degradation impurities in amisulpride oral solution
CN114088845B (en) * 2021-12-06 2022-08-16 广东金城金素制药有限公司 Analysis method for determining content of saccharin sodium and benzamide degradation impurities in amisulpride oral solution

Similar Documents

Publication Publication Date Title
US4596795A (en) Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US9333215B2 (en) Aqueous solution of 20(R)-ginsenoside RG3 pharmaceutical composition and process thereof
US20200347153A1 (en) Methods for forming inclusion complexes with hydrophilic beta-cyclodextrin derivatives and compositions thereof
AT500684A1 (en) MEDICAMENTS CONTAINING CARBOXYLIC ACIDS CONTAINING SULFUR OF SULFUR, AND THEIR USE FOR THE COMBUSTION OF RETROVIRUSES
US20100087392A1 (en) Complexes of ibuprofen, cyclodextrins and ternary agents and the use thereof in pharmaceutics
KR101563308B1 (en) Inclusion complexes of pinocembrin with cyclodextrin or its derivatives
EP3388055B1 (en) Method for preparing liposome
UEKAMA et al. Improvement of oral bioavailability of prednisolone by β-cyclodextrin complexation in humans
WO2021196659A1 (en) Glycosyl polyether compound liposome, preparation method therefor and medicine thereof
CN107714642A (en) A kind of oral solution of EV71 viruses and CVA16 viral inhibitors and preparation method thereof
WO2002030413A1 (en) Pharmaceutical solutions of modafinil compounds
TW201219370A (en) Agent for regulating the formation of nitrogen monoxide
CN111096947A (en) Oral amisulpride solution
CN104098763B (en) A kind of sulfhydrylation poloxamer derivative carrier and its preparation method and application
JPH0840880A (en) Medicine on basis of ketoprofen in soft gelatin capsule medicine and its preparation
KR0133517B1 (en) Etoposide preparation
RU2678772C2 (en) Cabazitaxel composition
JP2002526423A (en) Oxybutynin formulations and methods of use
CN112022806B (en) Water-in-oil hydroquinone emulsion and preparation method and application thereof
CN103159710B (en) Antiviral decalin derivate
CN108272745B (en) Metformin/ursolic acid nano oral preparation and preparation method thereof
JP2019506377A (en) Drug inclusion compound, preparation thereof, and production method therefor
CN108619163B (en) Polymer micelle containing naringin and preparation method thereof
TW201215412A (en) Stable pharmaceutical composition
CN108670950A (en) A kind of polydatin medicinal composition and preparation method thereof without organic solvent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200505

WD01 Invention patent application deemed withdrawn after publication